Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Comparative, Prospective, Multicentre Study of the Efficacy of Nivolumab + Ipilimumab Versus Pazopanib Alone in Patients With Metastatic or Unresectable Advanced Sarcoma of Rare Subtype (RAR-Immune)

NCT04741438 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT04741438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04741438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Comparative, Prospective, Multicentre Study of the Efficacy of Nivolumab + Ipilimumab Versus Pazopanib Alone in Patients With Metastatic or Unresectable Advanced Sarcoma of Rare Subtype (RAR-Immune)
Lead sponsor
Centre Leon Berard
Phase
Phase 3
Overall status
Unknown status
Start date
March 30, 2021
Completion date
August 31, 2025
Enrollment
96 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma